NCT00352924 2026-04-22
Agriculture Health Study
National Institutes of Health Clinical Center (CC)
Active not recruiting
Clinical Trials
482 trialsNCT03823534 2026-04-22
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
Phase 3 Recruiting
NCT04973605 2026-04-22
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT06876142 2026-04-22
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT07499128 2026-04-22
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Phase NA Not yet recruiting
NCT01816971 2026-04-21
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT02726750 2026-04-21
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
Recruiting
NCT05392946 2026-04-21
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
NCT05646576 2026-04-21
PEACE
Massachusetts General Hospital
Phase NA Recruiting
NCT06163898 2026-04-21
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
NCT06239272 2026-04-21
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06357988 2026-04-21
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT06649695 2026-04-21
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Phase 2 Recruiting
NCT07541391 2026-04-21
KOALA
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT07542418 2026-04-21
Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Not yet recruiting
NCT00106925 2026-04-20
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00339963 2026-04-20
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Completed
NCT00720785 2026-04-20
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01139476 2026-04-20
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
National Institutes of Health Clinical Center (CC)
Completed
NCT01676805 2026-04-20
Tissue Collection for Studies of Lymph Cancer
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03412877 2026-04-20
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT03777306 2026-04-20
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
University of Alabama at Birmingham
Phase NA Completed
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT04561492 2026-04-20
PentiMyelo
Nantes University Hospital
Phase 2 Active not recruiting
NCT05135351 2026-04-20
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
University of Nebraska
Phase NA Recruiting
NCT05909059 2026-04-20
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
Phase 2 Recruiting
NCT05969860 2026-04-20
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06179888 2026-04-20
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07532473 2026-04-20
REMAKE
The Royal Wolverhampton Hospitals NHS Trust
Not yet recruiting
NCT07539233 2026-04-20
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT04776395 2026-04-17
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Phase 2 Recruiting
NCT07280013 2026-04-17
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
C4 Therapeutics, Inc.
Phase 1 Recruiting
NCT07537049 2026-04-17
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT04392960 2026-04-16
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase NA Completed
NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
NCT04839003 2026-04-16
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT05640843 2026-04-16
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT06057402 2026-04-16
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06205953 2026-04-16
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06383143 2026-04-16
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06385652 2026-04-16
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06418750 2026-04-16
DELICATESSE
Nantes University Hospital
Phase NA Completed
NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting